Clinical trials: Infections, Respiratory
Pneumonia, COVID-19
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
- Conditions
- Pneumonia, COVID-19, Coronavirus
- Trial name
- FITE19 (NCT04439071)
- Testing
- PTC299, SOC
- Where
- 41 sites in United States, Australia and 9 more
- Volunteers
- 189 people
- Sponsor
- PTC Therapeutics
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
COVID-19
Losmapimod Safety and Efficacy in COVID-19
The therapeutic hypothesis for the use of losmapimod in COVID-19 disease is that increased mortality and severe disease is caused by p38 mitogen-activated protein kinase (MAPK)-mediated exaggerated acute inflammatory response…
- Trial name
- LOSVID (NCT04511819)
- Testing
- Losmapimod oral tablet
- Where
- 16 sites in United States, Brazil and 2 more
- Volunteers
- 52 people
- Sponsor
- Fulcrum Therapeutics
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Pneumonia
Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia
Primary Objective: To evaluate the clinical efficacy of pristinamycin at a dose of 2g x 2/day for 2 days then 1g x 3/day for 5 to 7 days versus amoxicillin 1g x3 /day for 7 to 9 days, 5 to 9 days after the end of treatment.
- Trial name
- NCT02332577
- Testing
- PRISTINAMYCIN XRP7263, Amoxicillin
- Where
- 19 sites in France, Tunisia
- Volunteers
- 161 people
- Sponsor
- Sanofi
Respiratory Syncytial Virus Infections
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
- Trial name
- NCT06573281
- Testing
- Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from…
- Trial name
- NCT04295551
- Testing
- Lopinavir / ritonavir tablets combined with Xiyanping injection, Lopinavir/ritonavir treatment
- Volunteers
- 80 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
COVID-19, Infectious Disease
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
This is a first in human clinical study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RQ-01. Adult patients who have tested positive for SARS-CoV-2 virus, have mild symptom(s) of COVID-19 disease…
- Conditions
- COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
- Trial name
- NCT06063330
- Testing
- RQ-001
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- Red Queen Therapeutics, Inc.
COVID-19
Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation
Q-POC SARS-CoV-2 moderate complexity PCR test performance evaluation
- Trial name
- NCT05614011
- Testing
- RT-PCR Test, Real-time PCR Test
- Where
- 3 sites in United States
- Volunteers
- 877 people
- Sponsor
- QuantuMDx Group Ltd
COVID-19 Infection
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection.
- Trial name
- NCT04639466
- Testing
- Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- Where
- 3 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- GeoVax, Inc.
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD…
- Trial name
- SCALA (NCT07725939)
- Testing
- Galvokimig
- Where
- 23 sites in United States, China
- Volunteers
- 402 people
- Sponsor
- UCB Biopharma SRL
Pneumonia, Bacterial Pneumonia
An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
The purpose of this study is to evaluate the effectiveness and safety of doripenem monohydrate in the treatment of patients with nosocomial (hospital-acquired) pneumonia.
- Conditions
- Pneumonia, Bacterial Pneumonia, Ventilator-Associated Pneumonia, Infections, Nosocomial
- Trial name
- NCT00502801
- Testing
- doripenem
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 185 people
- Sponsor
- PriCara, Unit of Ortho-McNeil, Inc.
Whole Cell Pertussis, Haemophilus Influenzae Type b
Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib
The purpose of this observer-blind study is to generate immunogenicity data with one formulation of GSK Biologicals' DTPw-HBV/Hib vaccine after the primary vaccination course and to demonstrate non-inferiority of this vaccine as…
- Conditions
- Whole Cell Pertussis, Haemophilus Influenzae Type b, Tetanus, Diphtheria
- Trial name
- NCT00473668
- Testing
- Zilbrix-Hib, Tritanrix™-HepB/ Hiberix™
- Where
- 3 sites in India
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD, Sepsis
Effect of Nebulized Bronchodilators on Heart Rate
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
- Conditions
- COPD, Sepsis, Shock
- Trial name
- NCT01151579
- Testing
- Levalbuterol, Albuterol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Fahim Khorfan, MD
Influenza
Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old
This study will evaluate the immunogenicity and the safety of PrepandrixTM in Korean subjects. A second group of subjects will receive FluarixTM vaccine as control.
- Trial name
- NCT01730378
- Testing
- Prepandrix™, Fluarix™
- Where
- 4 sites in South Korea
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Child
Japanese Study Evaluating Safety, Efficacy and Acceptability of Telithromycin in Children With Infections
The primary objective is to assess the safety of telithromycin (HMR 3647) (20% fine granules) 1g filling sachet in children with infections (Respiratory tract infections, Dermatological infections, Otorhinolaryngological…
- Trial name
- NCT00408135
- Testing
- telithromycin (HMR3647)
- Where
- Japan
- Volunteers
- 111 people
- Sponsor
- Sanofi
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents
This is a multicenter, randomized, and open-label study to evaluate the immune responses and safety profiles of children aged 6-12 years and adolescents aged 13-17 years receiving Ad5-nCoV (intramuscular injection) or Ad5-nCoV-IH…
- Trial name
- NCT05169008
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Where
- 2 sites in Chile
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID, Covid-19
Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19
Corona virus disease 2019 (COVID-19) is caused by SARS-CoV-2, a plus-sense single-stranded RNA virus. After an incubation period, which typically lasts for 5-6 days, COVID-19 patients present with a mild illness that lasts for a…
- Trial name
- NCT04465513
- Testing
- Best Standard of Care + CARDIO, Best Standard of Care
- Where
- 8 sites in Brazil, Canada and 3 more
- Volunteers
- 14 people
- Sponsor
- Hofseth Biocare ASA
Influenza
Drug Use Investigation for Arepanrix® (H1N1)
This post-marketing surveillance study is designed to collect safety information such as post-vaccination adverse events and adverse reactions from recipients of Arepanrix® (H1N1) Intramuscular Injection.
- Trial name
- NCT02069496
- Testing
- Arepanrix®
- Volunteers
- 3,405 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.